Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)
TWD 28.2
(7.22%)
TWD 28.2
(7.22%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.82 Billion TWD | 32.84% |
| 2022 | 1.37 Billion TWD | -7.76% |
| 2021 | 1.48 Billion TWD | 129.23% |
| 2020 | 648.47 Million TWD | -54.45% |
| 2019 | 1.42 Billion TWD | 15.05% |
| 2018 | 1.23 Billion TWD | -23.93% |
| 2017 | 1.62 Billion TWD | 70.43% |
| 2016 | 954.47 Million TWD | -5.2% |
| 2015 | 1 Billion TWD | -36.74% |
| 2014 | 1.59 Billion TWD | 19.74% |
| 2013 | 1.32 Billion TWD | -0.8% |
| 2012 | 1.33 Billion TWD | 91.8% |
| 2011 | 698.58 Million TWD | 1.57% |
| 2010 | 687.79 Million TWD | -38.48% |
| 2009 | 1.11 Billion TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.84 Billion TWD | 1.33% |
| 2024 Q2 | 1.64 Billion TWD | -10.76% |
| 2023 Q4 | 1.82 Billion TWD | 5.52% |
| 2023 FY | 1.82 Billion TWD | 32.84% |
| 2023 Q1 | 1.6 Billion TWD | 17.25% |
| 2023 Q3 | 1.72 Billion TWD | 7.06% |
| 2023 Q2 | 1.61 Billion TWD | 0.29% |
| 2022 Q2 | 1.41 Billion TWD | -12.02% |
| 2022 Q1 | 1.6 Billion TWD | 7.91% |
| 2022 FY | 1.37 Billion TWD | -7.76% |
| 2022 Q4 | 1.37 Billion TWD | 3.32% |
| 2022 Q3 | 1.32 Billion TWD | -5.97% |
| 2021 Q1 | 694.75 Million TWD | 7.14% |
| 2021 FY | 1.48 Billion TWD | 129.23% |
| 2021 Q3 | 1.44 Billion TWD | 46.65% |
| 2021 Q4 | 1.48 Billion TWD | 3.17% |
| 2021 Q2 | 982.46 Million TWD | 41.41% |
| 2020 Q3 | 581.98 Million TWD | -16.56% |
| 2020 FY | 648.47 Million TWD | -54.45% |
| 2020 Q1 | 1.4 Billion TWD | -1.5% |
| 2020 Q2 | 697.49 Million TWD | -50.26% |
| 2020 Q4 | 648.47 Million TWD | 11.43% |
| 2019 Q3 | 1.36 Billion TWD | -2.81% |
| 2019 Q4 | 1.42 Billion TWD | 4.39% |
| 2019 FY | 1.42 Billion TWD | 15.05% |
| 2019 Q1 | 1.27 Billion TWD | 3.18% |
| 2019 Q2 | 1.4 Billion TWD | 9.9% |
| 2018 Q1 | 1.48 Billion TWD | -8.52% |
| 2018 Q4 | 1.23 Billion TWD | 11.52% |
| 2018 Q3 | 1.1 Billion TWD | -27.92% |
| 2018 FY | 1.23 Billion TWD | -23.93% |
| 2018 Q2 | 1.53 Billion TWD | 3.45% |
| 2017 Q2 | 956.45 Million TWD | 6.33% |
| 2017 Q4 | 1.62 Billion TWD | -6.2% |
| 2017 FY | 1.62 Billion TWD | 70.43% |
| 2017 Q3 | 1.73 Billion TWD | 81.31% |
| 2017 Q1 | 899.48 Million TWD | -5.76% |
| 2016 Q4 | 954.47 Million TWD | -4.51% |
| 2016 FY | 954.47 Million TWD | -5.2% |
| 2016 Q3 | 999.53 Million TWD | 1.2% |
| 2016 Q2 | 987.7 Million TWD | 0.14% |
| 2016 Q1 | 986.32 Million TWD | -2.04% |
| 2015 FY | 1 Billion TWD | -36.74% |
| 2015 Q2 | 950.84 Million TWD | -2.57% |
| 2015 Q1 | 975.88 Million TWD | -38.68% |
| 2015 Q4 | 1 Billion TWD | 6.69% |
| 2015 Q3 | 943.66 Million TWD | -0.75% |
| 2014 Q3 | 1.54 Billion TWD | 6.91% |
| 2014 FY | 1.59 Billion TWD | 19.74% |
| 2014 Q4 | 1.59 Billion TWD | 3.29% |
| 2014 Q2 | 1.44 Billion TWD | 4.7% |
| 2014 Q1 | 1.37 Billion TWD | 3.57% |
| 2013 Q3 | 1.32 Billion TWD | -0.78% |
| 2013 Q4 | 1.32 Billion TWD | -0.06% |
| 2013 FY | 1.32 Billion TWD | -0.8% |
| 2013 Q1 | 1.27 Billion TWD | -4.48% |
| 2013 Q2 | 1.34 Billion TWD | 4.74% |
| 2012 FY | 1.33 Billion TWD | 91.8% |
| 2012 Q2 | 1.49 Billion TWD | 112.73% |
| 2012 Q3 | 1.35 Billion TWD | -8.87% |
| 2012 Q4 | 1.33 Billion TWD | -1.45% |
| 2012 Q1 | 701.28 Million TWD | 0.39% |
| 2011 Q4 | 698.58 Million TWD | 5.44% |
| 2011 Q2 | 691.94 Million TWD | 41.94% |
| 2011 Q1 | 487.49 Million TWD | -29.12% |
| 2011 FY | 698.58 Million TWD | 1.57% |
| 2011 Q3 | 662.54 Million TWD | -4.25% |
| 2010 FY | 687.79 Million TWD | -38.48% |
| 2010 Q4 | 687.79 Million TWD | 0.0% |
| 2009 FY | 1.11 Billion TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Apex Biotechnology Corp. | 500.07 Million TWD | -264.232% |
| Sinphar Pharmaceutical Co.,Ltd. | 2.85 Billion TWD | 36.163% |
| Panion & Bf Biotech Inc. | 1.32 Billion TWD | -37.559% |
| GenMont Biotech Incorporation | 204.05 Million TWD | -792.593% |
| Abnova (Taiwan) Corporation | 69.42 Million TWD | -2523.611% |
| Adimmune Corporation | 3.7 Billion TWD | 50.864% |
| Tanvex BioPharma, Inc. | 1.94 Billion TWD | 6.223% |
| Polaris Group | 1.46 Billion TWD | -24.347% |
| Energenesis Biomedical CO.,LTD. | 24.58 Million TWD | -7308.045% |
| UnicoCell Biomed Co., Ltd. | 89.48 Million TWD | -1935.397% |
| PELL Bio-Med Technology Co. Ltd. | 236.76 Million TWD | -669.293% |